.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,126,959

« Back to Dashboard

Details for Patent: 6,126,959

Title: Pharmaceutical composition for treating dysmenorrhea and premature labor
Abstract:The present invention teaches a composition comprising a .beta.-adrenergic agonist in a bioadhesive carrier. Preferably, the composition comprises terbutaline in polycarbophil. The present invention additionally teaches the local administration of a .beta.-adrenergic agonist for the purpose of treating or preventing dysmenorrhea or premature labor. Using this composition and the method of treatment provides sufficient local levels of the drug to provide therapeutic efficacy, but avoids many untoward adverse events.
Inventor(s): Levine; Howard L. (Oceanside, NY), Bologna; William J. (New York, NY), de Ziegler; Dominique (Paris, FR)
Assignee: Columbia Laboratories, Inc. (Aventura, FL)
Filing Date:Sep 01, 1998
Application Number:09/145,172
Claims:1. A pharmaceutical composition comprising a therapeutically effective amount of a .beta.-adrenergic agonist together with a pharmaceutically acceptable bioadhesive carrier, wherein the bioadhesive carrier is a cross-linked water-insoluble but water-swellable polycarboxylic acid polymer.

2. The composition of claim 1 wherein the .beta.-adrenergic agonist is terbutaline.

3. A pharmaceutical composition comprising a therapeutically effective amount of a .beta.-adrenergic agonist together with a pharmaceutically acceptable bioadhesive carrier, wherein the .beta.-adrenergic agonist is terbutaline and the bioadhesive carrier is a cross-linked water insoluble but water swellable polycarboxylic acid polymer.

4. The composition of claim 3, wherein the concentration of terbutaline is from 0.1 to 0.4% weight/weight.

5. The composition of claim 4, wherein the polymer is polycarbophil.

6. The composition of claim 5, wherein the .beta.-adrenergic agonist is terbutaline and the composition is prepared so that a dosage of about 1 to 1.5 g of composition will deliver from 1 to 4 mg of terbutaline.

7. A method of preventing or treating dysmenorrhea comprising administering

vaginally to a host in need thereof the pharmaceutical composition of claim 1.

8. The method of claim 7, wherein the .beta.-adrenergic agonist is terbutaline and the dosage of composition administered contains from 1 to 4 mg of terbutaline.

9. The method of claim 7, wherein the composition is administered every 12 to 48 hours during dysmenorrhea.

10. The method of claim 7, wherein the composition is administered every 12 to 48 hours beginning one day prior to the anticipated onset of dysmenorrhea and continuing during dysmenorrhea.

11. The method of claim 7, wherein the composition is administered every 24 hours during dysmenorrhea.

12. The method of claim 7, wherein the composition is administered every 24 hours beginning one day prior to the anticipated onset of dysmenorrhea and continuing during dysmenorrhea.

13. A pharmaceutical composition for vaginal administration of a treating agent to other than progesterone, achieve local efficacy without detrimental blood levels of the treating agent, comprising a therapeutically effective amount of said treating agent together with polycarbophil.

14. A method of delivering a treating agent, other than progesterone or an anti-sexually transmitted diseases agent, normally associated with potential undesired side effects at detrimental blood levels to a female subject comprising inserting a bioadhesive, cross-linked water-swellable but water-insoluble polycarboxylic acid polymer formulation with a therapeutically effective amount of said treating agent wherein the formulation releases the treating agent at a rate sufficient to achieve local efficacy without producing detrimental blood levels of the treating agent.

15. A pharmaceutical composition for vaginal administration of a treating agent during menses, comprising polycarbophil and a therapeutically effective amount of a treating agent.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc